ES2528055T3 - Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno - Google Patents

Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno Download PDF

Info

Publication number
ES2528055T3
ES2528055T3 ES10150763.0T ES10150763T ES2528055T3 ES 2528055 T3 ES2528055 T3 ES 2528055T3 ES 10150763 T ES10150763 T ES 10150763T ES 2528055 T3 ES2528055 T3 ES 2528055T3
Authority
ES
Spain
Prior art keywords
compound
diene
compounds
androsta
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10150763.0T
Other languages
English (en)
Spanish (es)
Inventor
Angela Brodie
Vincent Njar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
University of Maryland, College Park
Original Assignee
University of Maryland, Baltimore
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore, University of Maryland, College Park filed Critical University of Maryland, Baltimore
Application granted granted Critical
Publication of ES2528055T3 publication Critical patent/ES2528055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10150763.0T 2005-03-02 2006-03-02 Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno Expired - Lifetime ES2528055T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
US657390P 2005-03-02

Publications (1)

Publication Number Publication Date
ES2528055T3 true ES2528055T3 (es) 2015-02-03

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10150763.0T Expired - Lifetime ES2528055T3 (es) 2005-03-02 2006-03-02 Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno
ES06736460T Expired - Lifetime ES2353413T3 (es) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06736460T Expired - Lifetime ES2353413T3 (es) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.

Country Status (21)

Country Link
US (1) US7875599B2 (enExample)
EP (2) EP2206719B1 (enExample)
JP (2) JP5130453B2 (enExample)
KR (1) KR101380959B1 (enExample)
CN (2) CN103349664A (enExample)
AT (1) ATE482969T1 (enExample)
AU (1) AU2006218711B2 (enExample)
BR (1) BRPI0607523A2 (enExample)
CA (1) CA2599953C (enExample)
DE (1) DE602006017175D1 (enExample)
DK (2) DK2206719T3 (enExample)
EA (1) EA019560B1 (enExample)
ES (2) ES2528055T3 (enExample)
IL (3) IL185608A (enExample)
MX (1) MX2007010593A (enExample)
NZ (1) NZ561571A (enExample)
PL (2) PL1853619T3 (enExample)
PT (2) PT1853619E (enExample)
SI (2) SI2206719T1 (enExample)
WO (1) WO2006093993A1 (enExample)
ZA (1) ZA200708106B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
JP5130453B2 (ja) * 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド，ボルティモア 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
BRPI0920681A2 (pt) * 2008-10-28 2015-12-29 Biomarin Pharm Inc inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
WO2010091299A2 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EP2461814A4 (en) * 2009-08-07 2012-12-05 Tokai Pharmaceuticals Inc PROSTATE CANCER TREATMENT
AU2010319697B2 (en) * 2009-11-13 2016-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
BR112013017635A2 (pt) * 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2014165815A2 (en) * 2013-04-04 2014-10-09 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
KR20160058774A (ko) * 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES2700901B2 (es) * 2016-08-08 2019-08-06 Ind Chimica Srl Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno.
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
AU2019222651B2 (en) * 2018-02-13 2024-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
EP3752517B1 (en) * 2018-02-13 2025-04-09 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
AU2020393896A1 (en) 2019-11-26 2022-06-23 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
PT1660115E (pt) 2003-07-29 2011-08-24 Dompe Spa ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE
JP5130453B2 (ja) 2005-03-02 2013-01-30 ユニバーシティ オブ メリーランド，ボルティモア 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Also Published As

Publication number Publication date
JP2008536807A (ja) 2008-09-11
US20080280864A1 (en) 2008-11-13
MX2007010593A (es) 2008-02-20
DK2206719T3 (en) 2015-01-26
DK1853619T3 (da) 2011-01-10
PT2206719E (pt) 2015-02-05
JP2012255026A (ja) 2012-12-27
KR101380959B1 (ko) 2014-04-04
AU2006218711A1 (en) 2006-09-08
IL210480A0 (en) 2011-03-31
IL185608A (en) 2016-06-30
IL210480A (en) 2015-06-30
ATE482969T1 (de) 2010-10-15
AU2006218711A2 (en) 2006-09-08
IL210478A0 (en) 2011-03-31
IL185608A0 (en) 2008-01-06
EP1853619A4 (en) 2009-08-26
KR20070120119A (ko) 2007-12-21
PL1853619T3 (pl) 2011-03-31
EP2206719A3 (en) 2011-01-05
PT1853619E (pt) 2011-01-03
EA019560B1 (ru) 2014-04-30
EP2206719A2 (en) 2010-07-14
EP1853619B1 (en) 2010-09-29
PL2206719T3 (pl) 2015-03-31
EA200701872A1 (ru) 2008-06-30
US7875599B2 (en) 2011-01-25
SI2206719T1 (sl) 2015-03-31
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
EP2206719B1 (en) 2014-10-22
DE602006017175D1 (de) 2010-11-11
HK1115387A1 (en) 2008-11-28
CA2599953C (en) 2013-08-13
CN103349664A (zh) 2013-10-16
ZA200708106B (en) 2008-12-31
CA2599953A1 (en) 2006-09-08
JP5130453B2 (ja) 2013-01-30
NZ561571A (en) 2009-09-25
CN101155823A (zh) 2008-04-02
SI1853619T1 (sl) 2011-01-31
AU2006218711B2 (en) 2010-11-11
BRPI0607523A2 (pt) 2009-09-08
WO2006093993A1 (en) 2006-09-08
ES2353413T3 (es) 2011-03-01

Similar Documents

Publication Publication Date Title
ES2353413T3 (es) 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.
US10098896B2 (en) C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Bruno et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
ES2552087T3 (es) Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US9295679B2 (en) Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
ES2290984T3 (es) Inhibidores de la sintesis de androgenos.
US6200965B1 (en) 17-Azolyl steroids useful as androgren synthesis inhibitors
HK1115387B (en) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease